AnaptysBio, Inc.
ANAB
$26.58
$0.240.91%
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Revenue | 66.78% | 233.18% | -46.30% | -79.79% | -83.72% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 66.78% | 233.18% | -46.30% | -79.79% | -83.72% |
| Cost of Revenue | 48.97% | 32.46% | 22.70% | 4.56% | -9.85% |
| Gross Profit | -46.64% | -22.19% | -47.04% | -106.12% | -122.28% |
| SG&A Expenses | 25.43% | 39.58% | 52.96% | 61.48% | 55.60% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 42.53% | 34.19% | 29.34% | 15.51% | 1.88% |
| Operating Income | -40.30% | -26.56% | -48.67% | -90.75% | -97.05% |
| Income Before Tax | -27.14% | -9.60% | -33.31% | -80.13% | -122.68% |
| Income Tax Expenses | -116.67% | -- | -- | -- | -- |
| Earnings from Continuing Operations | -27.11% | -9.62% | -33.33% | -80.17% | -122.72% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -27.11% | -9.62% | -33.33% | -80.17% | -122.72% |
| EBIT | -40.30% | -26.56% | -48.67% | -90.75% | -97.05% |
| EBITDA | -40.57% | -26.70% | -48.99% | -91.61% | -98.02% |
| EPS Basic | -32.73% | -12.12% | -33.58% | -76.46% | -117.43% |
| Normalized Basic EPS | -30.00% | -14.84% | -37.64% | -84.16% | -111.90% |
| EPS Diluted | -32.78% | -12.39% | -33.79% | -76.36% | -117.21% |
| Normalized Diluted EPS | -30.00% | -14.84% | -37.64% | -84.16% | -111.90% |
| Average Basic Shares Outstanding | -4.38% | -1.94% | 0.39% | 2.56% | 2.67% |
| Average Diluted Shares Outstanding | -4.38% | -1.94% | 0.39% | 2.56% | 2.67% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
